The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Survival of patients with HER2-positive gastric cancer with introduction of trastuzumab.
Kohei Shitara
No relevant relationships to disclose
Yasushi Yatabe
No relevant relationships to disclose
Masato Sugano
No relevant relationships to disclose
Keitaro Matsuo
No relevant relationships to disclose
Chihiro Kondo
No relevant relationships to disclose
Daisuke Takahari
No relevant relationships to disclose
Takashi Ura
No relevant relationships to disclose
Masahiro Tajika
No relevant relationships to disclose
Kei Muro
No relevant relationships to disclose